Cite
HARVARD Citation
Hakim, J. et al. (2018). Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet infectious diseases. 18 (1), pp. 47-57. [Online].